Immunostimulatory vs. Immunomodulatory Why the Distinction Matters in Autoimmune Disease

Yoon Hang Kim, MD, MPH  |  www.directintegrativecare.com

The Problem with “Immune Boosting”

Walk into any health food store and you will see shelves of supplements promising to “boost” immunity. For an otherwise healthy person fighting a winter cold, that framing may be harmless marketing. For a patient with Hashimoto’s, lupus, rheumatoid arthritis, multiple sclerosis, Sjögren’s, psoriasis, or any other autoimmune condition, it is the wrong goal entirely.

The immune system in autoimmunity is not underactive. It is misdirected. The last thing we want to do is pour fuel on a fire that is already burning the wrong tissue. This is why I spend so much time in my practice separating immunostimulants from immunomodulators — and why patients often leave their first visit with a list of supplements to stop, not start.

The Immunostimulatory Camp (Use Caution or Avoid)

Immunostimulants broadly activate innate or adaptive immunity. They increase phagocytosis, NK cell counts, macrophage activity, or pro-inflammatory cytokines such as TNF-alpha. In acute infection in a healthy person, this can be useful. In autoimmunity, it can precipitate or worsen a flare.

A widely cited 2004 case series in Archives of Dermatology (Lee and Werth) documented autoimmune flares — including pemphigus, lupus, and Sjögren’s — associated with immunostimulatory herbal supplements, and proposed increased TNF-alpha production as a likely mechanism. A subsequent 2020 review in the dermatology literature reinforced the same concern for spirulina, Aphanizomenon flos-aquae (AFA / blue-green algae), chlorella, echinacea, and alfalfa.

Herbs and nutraceuticals I typically discourage in active autoimmunity:

• Echinacea (angustifolia, purpurea, pallida) — the German Commission E and the Merck Manual list autoimmune disease as a contraindication.
• Spirulina and Aphanizomenon flos-aquae (AFA, blue-green algae) — documented associations with autoimmune flares and dermatomyositis.
• Chlorella — similar immunostimulatory profile; reports of aggravating autoimmune conditions.
• Alfalfa (Medicago sativa) — contains L-canavanine and has been linked to lupus-like syndromes and lupus reactivation.
• High-dose astragalus (Astragalus membranaceus) used as a Th1 stimulant — context-dependent; often fine at culinary or broth doses, concerning at high immune-stim doses in Th1-dominant autoimmunity.
• Andrographis paniculata at sustained immune-stimulating doses, despite some positive RA data — worth individualizing.
• Cat’s claw (Uncaria tomentosa) — mixed signal; traditional use includes autoimmune conditions, but oxindole alkaloid fractions can stimulate T cells.

This is not a blanket ban. Clinical herbalists argue — fairly — that some of these plants have nuanced mechanisms and may even help certain autoimmune phenotypes in skilled hands. But in the usual primary care or integrative clinic setting, where we cannot monitor every cytokine pathway in real time, the safer default is to avoid broad, non-targeted immune stimulants in autoimmune patients.

The Immunomodulatory Camp (Generally Helpful)

Immunomodulators are different. Rather than pushing the immune system in one direction, they help restore balance — upregulating what is deficient, dampening what is excessive, and pushing the system back toward tolerance. Three of my favorites are medicinal mushrooms, low-dose naltrexone, and vitamin D.

1. Medicinal Mushrooms

Medicinal mushrooms are the classic example of immune modulation rather than stimulation. Their beta-glucans — particularly the branched (1,3)(1,6)-beta-D-glucans in the fungal cell wall — bind to pattern recognition receptors like Dectin-1 and CR3 on macrophages, dendritic cells, and NK cells. The downstream effect is not a blunt “on” switch, but a recalibration.

This bidirectional behavior is why most integrative oncologists and functional medicine clinicians consider beta-glucan-rich mushrooms compatible with, and often helpful in, autoimmune disease — with appropriate caution and monitoring.

Mushrooms with the strongest immunomodulatory evidence:

• Reishi (Ganoderma lucidum) — triterpenes and polysaccharides with anti-inflammatory and Treg-supportive effects; a Ganoderma tsugae study in NZB/W mice (a lupus model) showed reduced autoantibody formation and prolonged survival.
• Turkey Tail (Trametes versicolor / Coriolus versicolor) — PSK and PSP are the best-studied mushroom polysaccharides globally; PSK is an approved adjunct cancer therapy in Japan and has been studied in connective tissue disease.
• Maitake (Grifola frondosa) — D-fraction beta-glucan shows bidirectional modulation in clinical trials, enhancing or suppressing specific immune parameters depending on baseline.
• Shiitake (Lentinula edodes) — lentinan is well studied for immune modulation and has a long safety record.
• Cordyceps (Ophiocordyceps / Cordyceps militaris) — adaptogenic with anti-inflammatory and Treg-favoring effects.
• Lion’s Mane (Hericium erinaceus) — primarily neurotrophic via hericenones/erinacines, but also contains beta-glucans and is frequently used in MS, neuropathy, and autoimmune brain-fog contexts.

A reasonable caution: in patients on pharmacologic immunosuppression (biologics, high-dose steroids, post-transplant), I still review mushroom supplementation case by case, because bidirectional modulation can theoretically nudge in either direction.

2. Low Dose Naltrexone (LDN)

LDN (typically 1.5–4.5 mg nightly) is the best pharmaceutical example of immune modulation I know. Unlike standard-dose naltrexone used in addiction medicine, LDN produces a brief opioid receptor blockade followed by upregulation of endogenous endorphins, OGF-OGFr signaling, and modulation of Toll-like receptor 4 on microglia and macrophages.

Clinically, the result is an immune system that becomes less inflammatory and more regulated — not more suppressed. Patients with Hashimoto’s, Crohn’s disease, multiple sclerosis, fibromyalgia, complex regional pain syndrome, psoriasis, lupus, and a growing list of other conditions often report reduced flares, reduced fatigue, reduced pain, and improved quality of life. For many of my patients, LDN is the single highest-yield intervention I can offer.

Importantly, LDN does not meaningfully conflict with vitamin D or medicinal mushrooms. In my clinical experience and in the consensus of LDN-prescribing clinicians, these tools stack well. The main hard contraindications remain full-dose opioid therapy and a handful of specific interactions.

3. Vitamin D

Vitamin D is not simply an “immune booster.” It is an immunomodulatory hormone. It supports T-regulatory cell function, shifts dendritic cells toward a tolerogenic phenotype, and down-regulates inflammatory Th17 activity. Multiple meta-analyses and reviews associate low 25-hydroxyvitamin D levels with higher prevalence and severity of Hashimoto’s and other autoimmune diseases, and correcting deficiency has been shown to reduce thyroid antibody titers in a subset of patients.

The online warning that vitamin D “interferes with LDN” is not supported by the clinical literature I have reviewed. The concern, when it exists, is usually about very high, chronic pharmacologic dosing of vitamin D — not physiologic replacement to a mid-range 25-OH D target (often around 40–60 ng/mL, individualized).

My practical approach:

• Test 25-OH vitamin D before replacing — do not guess.
• Replace to a physiologic mid-range target, not a megadose target.
• Recheck every 3–6 months during active replacement; annually once stable.
• Consider co-factors: magnesium, vitamin K2, and adequate calcium intake from food.
• Reserve very high-dose protocols (e.g., the Coimbra protocol) for specialist settings with monitoring.

Putting It Together: A Clinical Framework

When I meet a new autoimmune patient — whether it is Hashimoto’s, Crohn’s, RA, lupus, or an overlap syndrome — here is how I think about their supplement stack:

• Remove the immunostimulants. Echinacea, spirulina, chlorella, AFA, alfalfa, and broad “immune booster” formulas come off the list first.
• Add or optimize immunomodulators. LDN, vitamin D (to a physiologic target), and medicinal mushroom beta-glucans are the core tools.
• Treat the root causes in parallel. Food triggers, gut dysbiosis, nutrient deficiencies, chronic infections, mold/CIRS, sleep, trauma, and stress physiology still have to be addressed. No supplement substitutes for root-cause work.
• Monitor. Symptoms, antibodies (TPO, TG, ANA, RF, anti-CCP, as relevant), inflammatory markers (hs-CRP, ESR, ferritin), and clinical function — not just lab numbers in isolation.
• Individualize. Th1/Th2/Th17/Treg phenotypes, genetics, concurrent medications, and life stage all shape the plan. A good integrative physician earns their keep in this individualization.

Yoon Hang Kim MD  •  www.directintegrativecare.com

Membership-based integrative telemedicine  •  Rooted in vision and sustainability